$4,750.00
Valued at more than $7.7bn in 2018, the Global Hearing Aids Market is growing at a healthy pace—in the upper single-digits, at a compound annual growth rate (CAGR) of nearly 7.5%. Growth will be driven by the increasing global prevalence of hearing loss. According to the World Health Organization (WHO), approximately 466 million people have disabling hearing loss worldwide, including 34 million who are children, and this number is expected to grow to nearly 630 million by 2030.
Executive Summary
This report provides an overview of hearing loss, hearing aids, and a comprehensive market and competitive analysis.
Valued at more than $7.7bn in 2018, the Global Hearing Aids Market is growing at a healthy pace—in the upper single-digits, at a compound annual growth rate (CAGR) of nearly 7.5%. Growth will be driven by the increasing global prevalence of hearing loss. According to the World Health Organization (WHO), approximately 466 million people have disabling hearing loss worldwide, including 34 million who are children, and this number is expected to grow to nearly 630 million by 2030.
Hearing aids have been around for decades; yet, it is a substantially underpenetrated market. A key to market growth is expanding access to those who do not have access or cannot afford hearing aids, in developing and developed markets alike, as well as technological improvements and marketing to younger patients.
Major limiters to growth include high expense/out-of-pocket pay, limited access in emerging markets, stigma, low compliance, technological limitations, inconvenience and requirement for multiple visits to the audiologist.
Overall growth of the hearing aids market will be driven by strong benefits (eg improved quality of life, social/mental health); lowered prices/online/mass retailer accessibility; and steadily improving hearing aid technology or innovations (eg artificial intelligence, improved speech/sound clarity, less interference, directional hearing technology, rechargeability, miniaturization/invisible hearing aid designs, etc.). Other market drivers include aggressive sales/marketing and education efforts, strong and growing retail/audiologist networks and audiology practice referrals targeting patients with all forms of hearing loss, and expanded access to more regulated/higher-quality yet lower-cost hearing aids (especially in the US market due to the new FDA OTC hearing aids law set to finalize by 2020).
This report provides the following useful information:
Markets covered by this analysis include the US, Japan, the five major EU markets (France, Germany, Italy, Spain, and the UK), and the Rest of World (RoW) markets, which include all other countries.
Executive Summary ……………………………………………………………………………………………… ES-1
i. Hearing loss prevalence ………………………………………………………………………………………..ES-1
ii. Hearing aid technology ………………………………………………………………………………………..ES-1
iii. Hearing aids market ……………………………………………………………………………………………ES-2
a. Market drivers and limiters……………………………………………………………………….ES-4
b. Competition – market leaders……………………………………………………………………ES-5
iv. Methodology……………………………………………………………………………………………………..ES-6
v. Bibliography ……………………………………………………………………………………………………….ES-8
Exhibit ES-1: Hearing aids market forecast ($m), 2018-23…………………………………………….. ES-3
1. Overview of Hearing Loss and Hearing Aids……………………………………………………………..1-1
1.1 Ear anatomy and the hearing process………………………………………………………………….. 1-1
1.2 Prevalence………………………………………………………………………………………………………… 1-2
1.3 Types of hearing loss………………………………………………………………………………………….. 1-3
1.4 Causes……………………………………………………………………………………………………………… 1-4
1.5 Diagnosis and treatment…………………………………………………………………………………….. 1-5
1.6 Hearing aid overview …………………………………………………………………………………………. 1-5
1.7 Bibliography ……………………………………………………………………………………………………. 1-14
Exhibit 1-1: Human ear anatomy……………………………………………………………………………….1-1
Exhibit 1-2: Examples of hearing aid styles………………………………………………………………….1-7
Exhibit 1-3: Differences between hearing aids and cochlear implants……………………………..1-12
Exhibit 1-4: Otofonix’s low cost APEX digital hearing amplifier………………………………………1-13
2. Hearing Aid Technology ……………………………………………………………………………………….2-1
2.1 Hearing aid portfolios by major manufacturer………………………………………………………. 2-1
2.1.1 The GN Group/GN Store Nord A/S ………………………………………………………… 2-2
2.1.2 Sonova Group …………………………………………………………………………………….. 2-4
2.1.3 Starkey Hearing Technologies……………………………………………………………… 2-10
2.1.4 William Demant Group ………………………………………………………………………. 2-12
2.1.5 WS Audiology A/S (previously Sivantos Group)……………………………………… 2-15
2.2 FDA Reauthorization Act of 2017 creates new category of OTC hearing aids…………… 2-17
2.3 Direct-to-consumer/lower-cost hearing aids……………………………………………………….. 2-19
2.3.1 Avento……………………………………………………………………………………………… 2-20
2.3.2 Audicus…………………………………………………………………………………………….. 2-20
2.3.3 Eargo ………………………………………………………………………………………………. 2-21
2.3.4 Miracle-Ear……………………………………………………………………………………….. 2-22
2.3.5 Ovation Hearing ………………………………………………………………………………… 2-22
2.4 Emerging technology ……………………………………………………………………………………….. 2-23
2.4.1 Decibel Therapeutics …………………………………………………………………………. 2-23
2.4.2 Earlens Corp……………………………………………………………………………………… 2-25
2.4.3 Frequency Therapeutics……………………………………………………………………… 2-28
2.5 Bibliography ……………………………………………………………………………………………………. 2-30
Exhibit 2-1: Leading hearing aid brands, by manufacturer………………………………………………2-1
Exhibit 2-2: The ReSound LiNX 3D and ReSound Smart 3D app………………………………………..2-3
Exhibit 2-3: The new Phonak Audéo Marvel ………………………………………………………………..2-7
Exhibit 2-4: The 100% invisible Lync …………………………………………………………………………..2-8
Exhibit 2-5: The Moxi All and Insera in-the-ear hearing aids……………………………………………2-9
Exhibit 2-6: Starkey Hearing & Activity Tracking hearing aid …………………………………………2-11
Exhibit 2-7: Starkey Invisible-in-Canal Hearing Aid………………………………………………………2-11
Exhibit 2-8: The Zerena 9 miniRITE rechargeable hearing aid…………………………………………2-12
Exhibit 2-9: Selected Opn hearing aids ……………………………………………………………………..2-13
Exhibit 2-10: The new Kaizn Personal AI Assistant ………………………………………………………2-14
Exhibit 2-11: The new Signia Styletto Connect……………………………………………………………2-16
Exhibit 2-12: The low-cost Audicus Clara …………………………………………………………………..2-21
Exhibit 2-13: The Eargo hearing aid ………………………………………………………………………….2-22
Exhibit 2-14: Images of the cochlea and stereocilia……………………………………………………..2-24
Exhibit 2-15: The Earlens hearing aid………………………………………………………………………..2-27
3. Market Analysis………………………………………………………………………………………………….3-1
3.1 Hearing aids market…………………………………………………………………………………………… 3-1
3.1.1 Market forecast: global………………………………………………………………………… 3-1
3.1.2 Market drivers and limiters ………………………………………………………………….. 3-3
3.1.3 Market forecast: by region …………………………………………………………………… 3-4
3.1.4 US market ………………………………………………………………………………………….. 3-6
3.1.5 Five major EU markets…………………………………………………………………………. 3-6
3.1.6 Japanese market…………………………………………………………………………………. 3-7
3.1.7 Rest of the world market……………………………………………………………………… 3-7
3.2 Competitive analysis………………………………………………………………………………………….. 3-7
3.2.1 Market share: global……………………………………………………………………………. 3-7
3.2.2 Market share: by region……………………………………………………………………….. 3-9
3.2.3 Hearing aid revenues: by geography ……………………………………………………. 3-10
3.3 Financials and corporate growth strategies ………………………………………………………… 3-12
3.3.1 The GN Group/GN Store Nord A/S ………………………………………………………. 3-12
3.3.2 Sonova Group …………………………………………………………………………………… 3-14
3.3.3 William Demant Group ………………………………………………………………………. 3-18
3.3.4 WS Audiology (previously Sivantos Group) …………………………………………… 3-21
3.4 Bibliography ………………………………………………………………………………………… 3-23
Exhibit 3-1: Hearing aids market forecast ($m), 2018-23 ………………………………………………..3-2
Exhibit 3-2: Hearing aids market, forecast sales by region ($m), 2018-23…………………………..3-5
Exhibit 3-3: Hearing aids market, global share by supplier ($m), 2018 ………………………………3-8
Exhibit 3-4: Hearing aids market, estimated share by supplier and region, 2018 …………………3-9
Exhibit 3-5: Manufacturers’ hearing aid revenues by geography, 2018 ……………………………3-10
Exhibit 3-6: The GN Group/GN Store Nord, revenues by segment, FY2018………………………3-13
Exhibit 3-7: Sonova, revenues by segment, FY2018…………………………………………………….3-16
Exhibit 3-8: William Demant, revenues by segment, FY2018 ………………………………………..3-19
Appendix A: company listing
© Pharma Intelligence UK Ltd. This document is a licensed product and is not to be reproduced or redistributed
Do you have a subscription to Datamonitor Healthcare, Biomedtracker or Meddevicetracker? You may already have access to these reports, contact your account manager or email pharma@informabi.com for further help or assistance.
Sign up to the Pharma Intelligence Report Store Newsletter to get the latest blogs, news, reports and discounts!